 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...171172173174175176177178179180181...208209» |
- ||| HRS9950 / Jiangsu Hengrui Pharma
New P1 trial: Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects (clinicaltrials.gov) - Jul 8, 2020
P1, N=104, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||| pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
🟣🟣🟣🐯 #OncVoice Pyrotinib💊 in #HER2-Mutant Advanced Lung Adenocarcinoma RR 30%, mPFS 6.9 months, mOS 14.4 months. One year PFS rate 22.5% Reactions from oncologists👍👎 @StephenVLiu @mlazqui @Dr_Ivanoncologo @FernandoOnco @M_Tagliamento Full list: https://t.co/teSEOIjvRe (Twitter) - Jul 8, 2020
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Apatinib plus retinoic acid as maintenance for children with relapsed stage 4 high-risk neuroblastoma: Two case reports. (Pubmed Central) - Jul 8, 2020
The outcomes from these cases suggest that apatinib plus isotretinoin might be an option for maintenance therapy in patients with recurrent high-risk NB.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial initiation date, Real-world evidence: RFA Plus Carrizumab vs Carrizumab Alone for HCC (clinicaltrials.gov) - Jul 7, 2020
P2, N=120, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
The outcomes from these cases suggest that apatinib plus isotretinoin might be an option for maintenance therapy in patients with recurrent high-risk NB. Initiation date: Jan 2020 --> Aug 2020
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial initiation date, Trial primary completion date: Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jul 7, 2020
P2/3, N=180, Not yet recruiting, Sponsor: Shanghai Proton and Heavy Ion Center
Initiation date: Jan 2020 --> Aug 2020 Trial completion date: May 2025 --> Sep 2025 | Initiation date: May 2020 --> Sep 2020 | Trial primary completion date: May 2024 --> Sep 2024
- |||||| AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Jul 7, 2020
P3, N=390, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial completion date: May 2025 --> Sep 2025 | Initiation date: May 2020 --> Sep 2020 | Trial primary completion date: May 2024 --> Sep 2024 Not yet recruiting --> Recruiting
- |||| Irene (pyrotinib) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
Enrollment open: Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer (clinicaltrials.gov) - Jul 7, 2020
P2, N=216, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Tyvyt (sintilimab) / Eli Lilly, Tuoyi (toripalimab) / Shanghai Junshi Bioscience, AiRuiKa (camrelizumab) / Incyte
Clinical, Journal, Real-World Evidence: Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. (Pubmed Central) - Jul 7, 2020
PD-1-targeted immunotherapy with Toripalimab, Camrelizumab or Sintilimab yielded a promising outcome in Chinese HBV patients with HCC; 2. Immunotherapy was well tolerated generally and had manageable side effects, which is worth of popularization and application in clinical practice.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date: Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Jul 7, 2020
P2, N=90, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Immunotherapy was well tolerated generally and had manageable side effects, which is worth of popularization and application in clinical practice. Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
- || SHR-1802 / Jiangsu Hengrui Pharma
Enrollment open, Metastases: A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours (clinicaltrials.gov) - Jul 6, 2020
P1, N=42, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022 Not yet recruiting --> Recruiting
- || AiTan (rivoceranib) / HLB Bio Group
New P1 trial: A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects (clinicaltrials.gov) - Jul 6, 2020
P1, N=18, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, PD(L)-1 Biomarker: CAPAP-lung: Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma (clinicaltrials.gov) - Jul 6, 2020
P2, N=63, Not yet recruiting, Sponsor: Hunan Cancer Hospital
- | Pegylated rhG-CSF (mecapegfilgrastim) / Jiangsu Hengrui Pharma
New P2 trial: Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma (clinicaltrials.gov) - Jul 6, 2020
P2, N=170, Not yet recruiting, Sponsor: First Hospital of Jilin University
- |||| pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
#OncoAlert RR to pyrotinib was 30%, mPFS 6.9 months, mOS 14.4 months. One year PFS rate 22.5%. Grade 3-4 TRAEs in 28% (20% grade 3 diarrhea). Need larger studies but good to see more options emerging; potentially an option in sequence with ADC trastuzumab deruxtecan. #LCSM (Twitter) - Jul 6, 2020
- |||| pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
Clinical: #OncoAlert Phase II trial of pyrotinib in previously treated #HER2 #NSCLC available @ASCO_pubs by Dr. Caicun Zhou. Relatively large trial for this population: enrolled 60 patients from 10/20/16 to 12/10/18. #LCSM https://t.co/MhR9O8NS1n (Twitter) - Jul 6, 2020
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, P2 data, Journal: Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. (Pubmed Central) - Jul 2, 2020
Apatinib is a TKI that specifically inhibits vascular endothelial growth factor receptor-2, which is domestically made in China. This phase II trial supports the use of apatinib in patients with advanced osteosarcoma progressing after chemotherapy.
- |||| perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
This company too.....www.dry-eye.eu #novaliq #evotears #novatears #dryeye #betaliq (Twitter) - Jul 2, 2020
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma. (Pubmed Central) - Jul 2, 2020
This phase II trial supports the use of apatinib in patients with advanced osteosarcoma progressing after chemotherapy. TACE combined with apatinib is a safe and promising treatment approach for patients with large HCC.
- ||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
Journal, Adverse events: Salvage therapy of reactive capillary hemangiomas: Apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer. (Pubmed Central) - Jul 2, 2020
The combination of camrelizumab and apatinib in the treatment of NSCLC reduced the incidence of RCHs. Apatinib appeared to be a salvage therapy of RCHs, which leads to rapid regression of RCHs with no impairment on the quality of life.
- || AiRuiKa (camrelizumab) / Incyte
Clinical, Journal: Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer. (Pubmed Central) - Jul 2, 2020
The median PFS was 5.1 months and OS was not reached. Camrelizumab administration combined with MWA was safe in the treatment of advanced NSCLC, and the combination improved the ORR of camrelizumab alone compared to previous reports.
- || AiTan (rivoceranib) / HLB Bio Group, paclitaxel / Generic mfg.
Clinical, Journal: A study on the efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced stage non-small cell lung cancer. (Pubmed Central) - Jul 2, 2020
Recombinant human endostatin combined with apatinib mesylate achieves a better therapeutic effect in the treatment of middle and advanced NSCLC, with improved immune resistance of patients and less side effects. Therefore, it is worthy of popularization and application in clinical practice.
- |||| AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Enrollment open: Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor (clinicaltrials.gov) - Jul 1, 2020
P2, N=205, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Therefore, it is worthy of popularization and application in clinical practice. Not yet recruiting --> Recruiting
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study (clinicaltrials.gov) - Jul 1, 2020
P2, N=50, Not yet recruiting, Sponsor: Sun Yat-sen University
- recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
New P2 trial: A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia (clinicaltrials.gov) - Jul 1, 2020
P2, N=8, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || edralbrutinib (TG-1701) / TG Therap
New P1 trial: A Phase I Study of SHR1459 in Healthy Subjects (clinicaltrials.gov) - Jul 1, 2020
P1, N=20, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
Clinical, Journal: Effects and safety of perfluorohexyloctane on the eye surface and corneal endothelium. (Pubmed Central) - Jul 1, 2020
Not yet recruiting --> Recruiting Topical treatment with F6H8 for dried eye disease did not alter the measured variables of the corneal endothelium, but showed improvement in corneal staining and satisfaction.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jun 30, 2020
P3, N=388, Not yet recruiting, Sponsor: Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy?Irinotecan Plus Platinum?and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer?SCLC? (clinicaltrials.gov) - Jun 30, 2020
P2, N=60, Recruiting, Sponsor: Peking Union Medical College Hospital
- | AiTan (rivoceranib) / HLB Bio Group, doxorubicin hydrochloride / Generic mfg.
Journal: Programmable Codelivery of Doxorubicin and Apatinib Using an Implantable Hierarchical-Structured Fiber Device for Overcoming Cancer Multidrug Resistance. (Pubmed Central) - Jun 29, 2020
The in vivo DOX biodistribution displays that the DOX accumulation in the tumor tissues achieves 17.82% after implanting the fiber device for 72 h, which is 6.36-fold higher than that of the intravenously injected DOX. Importantly, the fiber device shows an excellent antitumor effect on MDR tumor-bearing mice with low systemic toxicity.
- | AiTan (rivoceranib) / HLB Bio Group
Biomarker, Journal, Tumor microenvironment: Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer. (Pubmed Central) - Jun 29, 2020
Anti-cancer activity was evident after co-administration of low-dose apatinib and anti-PD-1 in a small cohort of patients with pretreated advanced NSCLC. Overall, our work shows the rationale for treatment of lung cancer with a combination of PD-1/PD-L1 blockade and low-dose apatinib.
- || AiRuiKa (camrelizumab) / Incyte
Biomarker, Clinical, Clinical data, Journal, PD(L)-1 Biomarker, IO Biomarker: Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody. (Pubmed Central) - Jun 29, 2020
Overall, our work shows the rationale for treatment of lung cancer with a combination of PD-1/PD-L1 blockade and low-dose apatinib. Serum LDH, which is readily available in routine clinical practice, is a potential marker for response and a powerful independent factor for survival in advanced ESCC patients treated with anti-PD-1 therapy.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Apatinib-induced hyperammonemic encephalopathy. (Pubmed Central) - Jun 29, 2020
We would like to draw attention to the potential risk of vascular endothelial growth factor receptor-tyrosine kinase inhibitors induced hyperammonemic encephalopathy even with a low dosage. Clinicians should be aware of any unexplained neurological syndrome after the initiation of apatinib in patients with hepatocellular carcinoma.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Emerging agents and regimens for hepatocellular carcinoma. (Pubmed Central) - Jun 28, 2020
The combination of an anti-PD-1 antibody and an anti-angiogenesis agent has shown more potent anti-tumor effects in early phase clinical trials and is now the hotspot in clinical studies. Furthermore, these agents are investigated in combination treatment with surgery or other loco-regional therapies in patients with early or intermediate-stage HCC.
- || carboplatin / Generic mfg., AiTan (rivoceranib) / HLB Bio Group, Abraxane (albumin-bound paclitaxel) / Otsuka, BMS
Clinical, Journal: First-line albumin-bound paclitaxel/carboplatin plus apatinib in advanced pulmonary sarcomatoid carcinoma: A case series and review of the literature. (Pubmed Central) - Jun 28, 2020
Nab-paclitaxel/carboplatin plus apatinib showed limited short-term efficacy in advanced, unresectable PSC. The rapid resistance of PSC to the current therapeutic regimen necessitates further researches, as more effective agents are urgently needed.
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
Clinical, P2 data, Journal: Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. (Pubmed Central) - Jun 28, 2020
The rapid resistance of PSC to the current therapeutic regimen necessitates further researches, as more effective agents are urgently needed. No abstract available
- | perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
Journal: From nano-seggregation to mesophases: probing the liquid structure of perfluoroalkylalkanes with Xe NMR spectroscopy. (Pubmed Central) - Jun 27, 2020
It is important to stress that nano-segregation is this case observed in liquids interacting exclusively through dispersion forces, unlike most common examples of segregation which are determined by hydrogen bonding and polarity. Given the simple molecular structure and interactions of the studied PFAA, we believe that the present results can have a general impact in understanding the early mechanisms of segregation, phase separation and self-assembly.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy. (Pubmed Central) - Jun 27, 2020
The most common treatment-related AEs were hand-foot syndrome (35.29%, 12/34), proteinuria (32.35%, 11/34), and hypertension (32.35%, 11/34). Apatinib is effective and well tolerated in stage IV osteogenic sarcoma patients after chemotherapy failure.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging. (Pubmed Central) - Jun 26, 2020
In conclusion, apatinib has similar antitumorigenic and antiangiogenic efficacy as sorafenib in HCC with less toxicity. These findings may provide preclinical evidence supporting the potential application of apatinib for the treatment of HCC patients.
- ||| perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
You will be in good company ..... read here https://t.co/Ff7z6we1KW #Novaliq #Betaliq #NovaTears #EvoTears #Ursapharm (Twitter) - Jun 26, 2020
- | Tykerb (lapatinib) / Novartis, pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
Journal: Pyrotinib versus lapatinib in HER2-positive breast cancer. (Pubmed Central) - Jun 26, 2020
These findings may provide preclinical evidence supporting the potential application of apatinib for the treatment of HCC patients. No abstract available
- || AiTan (rivoceranib) / HLB Bio Group, Avastin (bevacizumab) / Roche
Clinical, Journal: Apatinib treatment for symptomatic pseudoprogression after standard treatment for glioblastoma multiforme: a case report. (Pubmed Central) - Jun 25, 2020
Apatinib, a novel tyrosine kinase inhibitor, has anti-angiogenetic effect just as bevacizumab...Then the patient received postoperative temozolomide with concurrent chemoradiotherapy...In 12 months after the radiotherapy, progression of tumor in the primary site has not been discovered. Apatinib showed a good therapeutic effect and tolerance for the development of pseudoprogression advances with obvious symptoms.
- |||||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P3 trial: PYRAMID-1: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (clinicaltrials.gov) - Jun 25, 2020
P3, N=150, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS (clinicaltrials.gov) - Jun 25, 2020
P2, N=20, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- || Zynyz (retifanlimab-dlwr) / Incyte, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Reolysin (pelareorep) / Oncolytics, Andrus Reo
New P2 trial, IO biomarker: INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study (clinicaltrials.gov) - Jun 23, 2020
P2, N=25, Not yet recruiting, Sponsor: Rutgers, The State University of New Jersey
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / Elevar Therapeutics
Enrollment open: A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 23, 2020
P2, N=46, Recruiting, Sponsor: Xin-Hua Xu
Apatinib showed a good therapeutic effect and tolerance for the development of pseudoprogression advances with obvious symptoms. Not yet recruiting --> Recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1/2 trial: A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) (clinicaltrials.gov) - Jun 23, 2020
P1/2, N=40, Recruiting, Sponsor: Zhejiang Cancer Hospital
- ||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P1 trial: SHR-A1811-I-101: A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - Jun 23, 2020
P1, N=226, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| AiTan (rivoceranib) / HLB Bio Group
Trial completion date, Metastases: ANGEL: A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer (clinicaltrials.gov) - Jun 23, 2020
P3, N=460, Active, not recruiting, Sponsor: Elevar Therapeutics
Not yet recruiting --> Recruiting Trial completion date: Mar 2020 --> Jul 2020
- | AiTan (rivoceranib) / HLB Bio Group
Trial primary completion date, Tumor mutational burden: LSK-AM107: A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer (clinicaltrials.gov) - Jun 23, 2020
P1, N=30, Active, not recruiting, Sponsor: Elevar Therapeutics
Trial completion date: Mar 2020 --> Jul 2020 Trial primary completion date: Jun 2020 --> Sep 2020
- || AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed, Trial completion date, Trial primary completion date: CAPTAIN: SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. (clinicaltrials.gov) - Jun 23, 2020
P2, N=155, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial primary completion date: Jun 2020 --> Sep 2020 Recruiting --> Active, not recruiting | Trial completion date: Mar 2020 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Jun 2020